ondansetron has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ladizinski, B | 1 |
| Bazakas, A | 1 |
| Olsen, EA | 1 |
1 other study available for ondansetron and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
Topics: Aged; Antipruritics; Aprepitant; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Inte | 2012 |